Vitality
PT-141 / Oxytocin / Tesamorelin
Peptide blend
PT-141, Oxytocin and Tesamorelin blend
Research context
This preparation combines three peptides acting at unrelated receptor systems: the melanocortin receptors, the oxytocin receptor, and the GHRH receptor. Each is characterised independently in the published literature.
Common assays: Component identity by LC-MS · Purity per component
Specification
| Designation | Peptide blend |
|---|---|
| Full name | PT-141, Oxytocin and Tesamorelin blend |
| Components | PT-141 (Bremelanotide) · Oxytocin · Tesamorelin |
| Formats | 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Supplied in metered spray format |
| Storage | Refrigerated 2–8 °C, protected from light |
| Current lot | PTO10310N1125 → |
Common questions
How are three-component blends analysed?
By chromatographic separation with mass confirmation for each component. Peaks must be resolved for individual quantification, which is why blend certificates report per-component results.
Same pathway
Related compounds
PT-141
Bremelanotide
A cyclic heptapeptide melanocortin receptor agonist studied in MC3R and MC4R signalling.
Melanotan II
Melanotan-II
A cyclic α-MSH analogue studied as a non-selective melanocortin receptor agonist.
Kisspeptin
KISS1-derived peptide
A decapeptide fragment of the KISS1 gene product, studied in GnRH neuron signalling.